Form 4: Catheter Precision Director Converts Preferred Stock

Sentiment:

Insider Transaction Report


Catheter Precision Director James Joseph Caruso converted Series X Convertible Preferred Stock into 41 shares of common stock.

Summary

  • James Joseph Caruso, a Director of Catheter Precision, Inc. (VTAK), completed a conversion transaction.
  • On December 5, 2025, Caruso converted 7.932 shares of Series X Convertible Preferred Stock.
  • This conversion resulted in the acquisition of 41 shares of the company's Common Stock.
  • The transaction price for the acquired common stock was reported as $0, indicating it was obtained through conversion rather than a cash purchase.
  • Following this transaction, Caruso directly holds 50 shares of Common Stock and no Series X Convertible Preferred Stock.
  • The Series X Convertible Preferred Stock has no expiration date.

Sentiment

Score: 5

Explanation: The filing reports a routine insider conversion of preferred stock to common stock, which is generally neutral in sentiment. The small number of shares involved limits its significance.

Positives

  • The conversion simplifies the capital structure by reducing the number of preferred shares and increasing common stock ownership by a director.

Negatives

  • No direct negatives are apparent from this routine insider conversion transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape for Catheter Precision, Inc. It reflects an individual director's portfolio management.

Related Party Transactions

  • James Joseph Caruso, a Director of Catheter Precision, Inc., engaged in a transaction involving the company's securities.

Stakeholder Impact

  • Shareholders: A minor increase in the number of outstanding common shares due to the conversion, which is unlikely to have a material impact on per-share metrics given the small quantity.

Key Dates

DateDescription
12/05/2025Date of transaction (conversion of Series X Convertible Preferred Stock to Common Stock)
12/08/2025Date the Form 4 was signed by the reporting person

Keywords

Catheter Precision, VTAK, Form 4, Insider Transaction, Stock Conversion, Director, Beneficial Ownership, Preferred Stock, Common Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.